Ante Tonkic

Ante Tonkic

Auto-generated profile, based on publicly available information

Ante Tonkic

Department of Gastroenterology, University Hospital of Split, Split, Croatia

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2012 in Helicobacter
Verified
Journal Article
Closed access
PDF file
ATAnte Tonkic
Ante Tonkic
MTMarija Tonkic
Marija Tonkic
PLPhilippe Lehours
Philippe Lehours
FMFrancis Mégraud
Francis Mégraud

1 May 2005 in Forensic Science International
Verified
Journal Article
Closed access
ZSZeljko Sundov
Zeljko Sundov
ZNZeljko Nincevic
Zeljko Nincevic
MDMarija Definis-Gojanovic
Marija Definis-Gojanovic
MGMerica Glavina-Durdov
Merica Glavina-Durdov
IJIvana Jukic
Ivana Jukic
ATAnte Tonkic
Ante Tonkic

24 September 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IHIvana Tadin Hadjina
Ivana Tadin Hadjina
PZPiero Marin Zivkovic
Piero Marin Zivkovic
Andrija MateticAndrija Matetic
Andrija Matetic
Doris RusicDoris Rusic
Doris Rusic
MVMarino Vilovic
Marino Vilovic
Josko BozicJosko Bozic
Josko Bozic
Limited evidence exists regarding cognitive and psychomotor function in patients with inflammatory bowel disease (IBD). Therefore, we aimed to compare the neurocognitive and psychomotor function of 60 IBD patients with 60 age/sex-matched controls. Computer-based instrument Complex Reactinometer Drenovac (CRD) was used for assessment of cognitive domains: convergent thinking (simple mathematical tasks; CRD-11), perceptive abilities (light signal position discrimination; CRD-311) and sophisticated operative thinking (complex psychomotor coordination; CRD-411). The most important analyzed parameters were total test solving time (TTTS); minimal time of particular test solving (TMIN) and total number of wrong reactions (NER). Performance in all three cognitive tests showed statistically significantly longer TTTS and TMIN in IBD patients (P < 0.05), while there was no significant difference in NER. Aforementioned findings were adjusted for BMI, age and duration of education. Our study has shown impaired neurocognitive and psychomotor function in IBD patients compared to controls, especially in mental processing speed and mental endurance of perceptive abilities, convergent thinking and complex operative thinking.

1 January 2007 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
IDIvan Dobric
Ivan Dobric
PDPetar Drvis
Petar Drvis
IPIgor Petrovic
Igor Petrovic
DSDrazen Shejbal
Drazen Shejbal
LBLuka Brcic
Luka Brcic
PSPredrag Sikiric
Predrag Sikiric
Seven or fourteen days or twelve months after suturing one tube into the pyloric sphincter (removed by peristalsis by the seventh day), rats exhibit prolonged esophagitis with a constantly lowered pressure not only in the pyloric, but also in the lower esophageal sphincter and a failure of both sphincters. Throughout the esophagitis experiment, gastric pentadecapeptide BPC 157 (PL 14736) is given intraperitoneally once a day (10 μg/kg, 10 ng/kg, last application 24 h before assessment), or continuously in drinking water at 0.16 μg/ml, 0.16 ng/ml (12 ml/rat per day), or directly into the stomach 5 min before pressure assessment (a water manometer connected to the drainage port of a Foley catheter implanted into the stomach either through an esophageal or duodenal incision). This treatment alleviates i) the esophagitis (macroscopically and microscopically, at either region or interval), ii) the pressure in the pyloric sphincter, and iii) the pressure in the lower esophageal sphincter (cmH2O). In the normal rats it increases lower esophageal sphincter pressure, but decreases the pyloric sphincter pressure. Ranitidine, given using the same protocol (50 mg/kg, intraperitoneally, once daily; 0.83 mg/ml in drinking water; 50 mg/kg directly into the stomach) does not have an effect in either rats with esophagitis or in normal rats.

23 July 2008 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
SSSandra Skorjanec
Sandra Skorjanec
ZDZdravko Dolovski
Zdravko Dolovski
IKIvan Kocman
Ivan Kocman
LBLuka Brcic
Luka Brcic
ABAlenka Blagaic Boban
Alenka Blagaic Boban
PSPredrag Sikiric
Predrag Sikiric

1 January 2006 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
IPIgor Petrovic
Igor Petrovic
IDIvan Dobric
Ivan Dobric
PDPetar Drvis
Petar Drvis
DSDrazen Shejbal
Drazen Shejbal
LBLuka Brcic
Luka Brcic
PSPredrag Sikiric
Predrag Sikiric
We report a simple novel rat model that combines prolonged esophagitis and parallel sphincters failure. The anti-ulcer gastric pentadecapeptide BPC 157, which was found to be stable in gastric juice, and is being evaluated in inflammatory bowel disease trials, is an anti-esophagitis therapy that recovers failed sphincters. Twelve or twenty months after the initial challenge (tubes sutured into sphincters for one week and then spontaneously removed by peristalsis), rats exhibit prolonged esophagitis (confluent hemorrhagic and yellowish lesions, thinner epithelium and superficial corneal layer, with stratification derangement); constantly lowered pressure of both sphincters (assessed by using a water manometer connected to the drainage port of a Foley catheter implanted into the stomach either through esophageal or duodenal incision); and both lower esophageal and pyloric sphincter failure. Throughout the esophagitis experiment, BPC 157 was given at either 10 μg/kg, i.p., once a day (last application 24 h before assessment) or alternatively, it was given continuously in drinking water at 0.16 μg/ml (12 ml/rat). This treatment recovers i) esophagitis (macroscopically and microscopically, at either region or investigated time period) and ii) pressure in both sphincters (cmH2O). In addition, BPC 157 (10 μg/kg) or saline (1 ml/rat, 5 ml/kg) was specifically given directly into the stomach; pressure assessment was performed at 5 min thereafter. The effect of BPC 157 is specific because in normal rats, it increases lower esophageal sphincter-pressure, but decreases pyloric sphincter-pressure. Ranitidine, given as the standard drug using the same protocol (50 mg/kg, i.p., once daily; 0.83 mg/ml in drinking water; or 50 mg/kg directly into the stomach) had no effect.